Last reviewed · How we verify
recurrent glioblastoma
Approved treatments
Clinical guidelines
- FDA label — any
ZIRABEV is indicated for the treatment of recurrent glioblastoma (GBM) in adults. - FDA label — any
MVASI is indicated for the treatment of recurrent glioblastoma (GBM) in adults.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- recurrent glioblastoma patent landscape — cliff calendar, originator estates, attackable patents
- recurrent glioblastoma treatment landscape brief
- recurrent glioblastoma treatment updates RSS
Frequently asked questions about recurrent glioblastoma
What are the treatment guidelines for recurrent glioblastoma?
FDA label publishes guidelines for recurrent glioblastoma. 2 guideline references tracked.
Related
- Treatment landscape: recurrent glioblastoma patent cliff · recurrent glioblastoma CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing